Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
type: Dataset
description: International audience
landing page: 0085-2538
keyword: clinical-nephrology
keyword: glomerulopathy
keyword: infoeu-reposemanticsarticle
keyword: journal-articles
keyword: mesh-adolescent
keyword: mesh-adult
keyword: mesh-aged
keyword: mesh-antibodies-monoclonal-murine-derived
keyword: mesh-antigens-cd19
keyword: mesh-antigens-cd20
keyword: mesh-female
keyword: mesh-humans
keyword: mesh-immunosuppressive-agents
keyword: mesh-male
keyword: mesh-middle-aged
keyword: mesh-nephrosis-lipoid
keyword: mesh-prednisone
keyword: mesh-recurrence
keyword: mesh-retrospective-studies
keyword: nephrotic-syndrome
keyword: sdvbbmgtplife-sciences-q-biobiochemistry-molecular-biologygenomics-q-biogn
issued: 2026-05-07T19:15:32.382403
modified: 2026-05-07T19:15:32.382408
language: en
contact point: Organization
  fn: CCSD

test_moissonnage_selune
type: Agent

Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
type: Distribution
format: HTML
access URL: https://inserm.hal.science/inserm-00919110
issued: 2026-05-07T19:15:32.396674
modified: 2026-05-07T19:15:32.361423